JP5087541B2 - シグナルペプチドを用いない、細菌からの抗体分泌 - Google Patents

シグナルペプチドを用いない、細菌からの抗体分泌 Download PDF

Info

Publication number
JP5087541B2
JP5087541B2 JP2008522802A JP2008522802A JP5087541B2 JP 5087541 B2 JP5087541 B2 JP 5087541B2 JP 2008522802 A JP2008522802 A JP 2008522802A JP 2008522802 A JP2008522802 A JP 2008522802A JP 5087541 B2 JP5087541 B2 JP 5087541B2
Authority
JP
Japan
Prior art keywords
antibody
host cell
polypeptide
antibodies
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008522802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510998A5 (cg-RX-API-DMAC7.html
JP2009510998A (ja
Inventor
ヤラントン，ジェフリー
ベビントン，クリストファー・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanigen Inc
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of JP2009510998A publication Critical patent/JP2009510998A/ja
Publication of JP2009510998A5 publication Critical patent/JP2009510998A5/ja
Application granted granted Critical
Publication of JP5087541B2 publication Critical patent/JP5087541B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2008522802A 2005-07-22 2006-07-07 シグナルペプチドを用いない、細菌からの抗体分泌 Expired - Fee Related JP5087541B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70190205P 2005-07-22 2005-07-22
US60/701,902 2005-07-22
US11/273,906 2005-11-14
US11/273,906 US8211648B2 (en) 2005-07-22 2005-11-14 Secretion of antibodies without signal peptides from bacteria
PCT/US2006/026334 WO2007018853A2 (en) 2005-07-22 2006-07-07 Secretion of antibodies without signal peptides from bacteria

Publications (3)

Publication Number Publication Date
JP2009510998A JP2009510998A (ja) 2009-03-19
JP2009510998A5 JP2009510998A5 (cg-RX-API-DMAC7.html) 2010-05-20
JP5087541B2 true JP5087541B2 (ja) 2012-12-05

Family

ID=37679517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522802A Expired - Fee Related JP5087541B2 (ja) 2005-07-22 2006-07-07 シグナルペプチドを用いない、細菌からの抗体分泌

Country Status (11)

Country Link
US (2) US8211648B2 (cg-RX-API-DMAC7.html)
EP (1) EP1907610B1 (cg-RX-API-DMAC7.html)
JP (1) JP5087541B2 (cg-RX-API-DMAC7.html)
KR (1) KR101014891B1 (cg-RX-API-DMAC7.html)
CN (1) CN101568647B (cg-RX-API-DMAC7.html)
AU (1) AU2006276823B2 (cg-RX-API-DMAC7.html)
CA (1) CA2615776C (cg-RX-API-DMAC7.html)
IL (1) IL188889A (cg-RX-API-DMAC7.html)
NZ (1) NZ565126A (cg-RX-API-DMAC7.html)
SG (1) SG177895A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007018853A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211648B2 (en) * 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR101824512B1 (ko) 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
US20100272736A1 (en) 2009-02-04 2010-10-28 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
AU2010313621C1 (en) 2009-10-14 2015-11-26 Humanigen, Inc. Antibodies to EphA3
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
JP5957443B2 (ja) * 2011-03-28 2016-07-27 長瀬産業株式会社 フェリチンの製造方法
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
CN104995341B (zh) 2013-01-24 2018-09-07 埃布特拉斯有限公司 基于蛋白结合的fv文库及其制备方法
WO2015189477A1 (en) * 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US20190037816A1 (en) * 2016-01-13 2019-02-07 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2146572T3 (es) 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0404003A3 (en) 1989-06-19 1991-10-16 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
JPH07289267A (ja) * 1994-04-25 1995-11-07 Oriental Yeast Co Ltd 発現増強方法
US5824502A (en) * 1996-03-28 1998-10-20 Mitsui Chemicals, Inc. Method for secretory production of protein
JPH09313191A (ja) 1996-03-28 1997-12-09 Mitsui Petrochem Ind Ltd 蛋白質の分泌生産法
PT1157041E (pt) * 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
DE10325026B4 (de) 2003-06-02 2013-04-18 Genencor International,Inc. Bakterien mit erhöhter Proteinsekretion, Nukleotidsequenzen codierend für ein SecA Protein mit erhöhter Proteinsekretion sowie Verfahren zur Produktion von Proteinen
US20040266993A1 (en) 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
CA2535971C (en) * 2003-08-20 2018-04-10 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US7981843B2 (en) * 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US8211648B2 (en) * 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria

Also Published As

Publication number Publication date
AU2006276823A1 (en) 2007-02-15
CN101568647B (zh) 2012-10-03
US9127046B2 (en) 2015-09-08
US20070020685A1 (en) 2007-01-25
CN101568647A (zh) 2009-10-28
US20120309055A1 (en) 2012-12-06
CA2615776A1 (en) 2007-02-15
CA2615776C (en) 2014-05-13
NZ565126A (en) 2011-03-31
KR20080031452A (ko) 2008-04-08
EP1907610A4 (en) 2009-12-23
KR101014891B1 (ko) 2011-02-15
EP1907610B1 (en) 2013-09-11
IL188889A (en) 2014-09-30
IL188889A0 (en) 2008-04-13
AU2006276823B2 (en) 2010-04-22
EP1907610A2 (en) 2008-04-09
WO2007018853A3 (en) 2009-04-16
HK1113393A1 (en) 2008-10-03
US8211648B2 (en) 2012-07-03
WO2007018853A2 (en) 2007-02-15
JP2009510998A (ja) 2009-03-19
SG177895A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
US9127046B2 (en) Secretion of antibodies without signal peptides from bacteria
Pardon et al. A general protocol for the generation of Nanobodies for structural biology
Salema et al. Selection of single domain antibodies from immune libraries displayed on the surface of E. coli cells with two β-domains of opposite topologies
US8067179B2 (en) Immunoglobulin libraries
US7829684B2 (en) Methods for producing soluble membrane-spanning proteins
US20050008625A1 (en) Antibody affinity engineering by serial epitope-guided complementarity replacement
JP4303596B2 (ja) ポリペプチドを発現させるための真核生物シグナル配列およびポリペプチド提示ライブラリー
US8629245B2 (en) Immunoglobulin Fc libraries
Tsurushita et al. Humanization of a chicken anti-IL-12 monoclonal antibody
JPH06508511A (ja) 特異的な結合ペアーの構成員の製造方法
JP2011178691A (ja) カテニン結合プローブとその用途
JP2009520468A (ja) 融合タンパク質ライブラリーの作製法およびスクリーニング法、ならびにそれらの使用
JP2004533264A (ja) バクテリオファージのシグナルペプチドをコードする発現ベクター
Zhang et al. Construction of a full-length antibody phage display vector
HK1113393B (en) Secretion of antibodies without signal peptides from bacteria
JP7778307B2 (ja) ウェルシュ菌エンテロトキシンの検出方法
CN121698999A (zh) 一种用于布鲁氏菌抗原夹心法检测的成套单克隆抗体及其应用
Deen Isolation of Human Endoplasmic Reticulum Antibodies Using Phage Display Technology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120821

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120910

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees